Patricia Inacio, PhD,  science writer—

Myasthenia gravis patients appear to have lower levels of vitamin D than the general population, a study confirmed. The confirmation suggested that doctors need to monitor patients’ vitamin D levels to reduce the chance they will have additional autoimmune responses that can worsen their condition, the researchers said. Their study,…

Blood levels of a microRNA called miR-150-5p have been identified as a potential biomarker for AChR-positive myasthenia gravis, after surgical treatment was found to reduce its levels in a study. The study, “Thymectomy lowers the myasthenia gravis biomarker miR-150-5p,” was published in the journal Neurology…

Using robotic-assisted surgery to remove the thymus without putting a patient on an  immunosuppressant afterwards leads to higher myasthenia gravis (MG) improvement and remission rates, a study suggests. The study, “Independent long-term result of robotic thymectomy for myasthenia gravis, a single center experience” was published in the Journal of Thoracic…

Ra Pharmaceuticals, which is now enrolling patients with generalized myasthenia gravis into a Phase 2 clinical trial, joined millions of health care advocates worldwide for the 11th annual Rare Disease Day, held to raise awareness and public understanding of rare diseases. The 2018 Rare Disease Day had as a…

Researchers in Japan wrote about a new case study where treatment with the immunotherapy Opdivo (nivolumab) led to a relapse of myasthenia gravis (MG). The study is a new piece of evidence supporting previous concerns that this type of treatment may increase risk for autoimmune disorders. The…

Women with a rare form of myasthenia gravis (MG) called muscle specific kinase (MuSK) MG can have healthy pregnancies without jeopardizing outcomes or increasing the risk of disease worsening, a small group study suggests. The study, “MuSK Myasthenia gravis and Pregnancy,” was published in the journal Neuromuscular Disorders.

GT Biopharma has launched a proof-of-concept Phase 1 trial of its investigational therapy GTP-004 for the treatment of myasthenia gravis. The trial’s primary goal is to demonstrate the therapy improves the gastrointestinal side effects of current treatments. “I am very pleased that GT Biopharma’s first clinical trial in patients with…

Cancer immunotherapies that boost the immune system’s response, such as Opdivo (nivolumab), may increase risk for autoimmune disorders, including myasthenia gravis, a case report study suggests. The findings of the case are reported in “Myasthenia Gravis Induced by Nivolumab: A Case Report,” published in the journal Cureus. Opdivo…

Researchers in Taiwan have found that first-degree relatives of individuals with myasthenia gravis have a higher risk of developing the disease. The risk is greater for patients’ siblings, the study found. The study, “Familial aggregation of myasthenia gravis in affected families: a population-based study,” appeared in the journal Clinical…

Researchers have found that the drug ONX-0914 halts disease progression in an animal model of myasthenia gravis by altering immune responses. The study, “ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response,” was published in the Journal of Neuroimmunology. The buildup of…